Abstract: The present invention discloses a synthesis method of lactide by confinement effect catalysis of crystalline porous polymer material, wherein the method comprising: (I) synthesis of catalyst; (II) synthesis of lactide by confinement effect catalysis; and (III) purification of lactide. In the present invention, a yield of L-lactide by catalysis of L-lactic acid by crystalline polymers is as high as 85.6%, which is 10% higher than the yield of lactide by H-? molecular sieve reported in documents currently available; it is easy to prepare the crystalline porous polymer material catalyst, which is environmental friendly, has a high yield and is recyclable, for consecutive 7 times the catalysis yield is maintained to be higher than 70%, and catalysis yield conservation rate is far higher than catalysis effects of catalysts reported in documents currently available.

Abstract: The invention provides a catalyst comprising 1) Ru0 and 2) Pd0, Pt0, Rh0, or Ir0, on a solid support. The catalyst is useful for water purification applications. In particular, the catalyst is useful for reducing ClO3? and ClO2? from water. The invention also provides catalysts that are useful for reducing nitrate in a water supply and methods for their use.

Abstract: A technique for providing search results may include determining a first entity type, a second entity type, and a relationship type based on a compositional query. The technique may also include identifying nodes of a knowledge graph corresponding to entity references of the first entity type and entity references of the second entity type. The technique may also include determining from the knowledge graph an attribute value corresponding to the relationship type for each entity reference of the first entity type and for each entity reference of the second entity type. The technique may also include comparing the attribute value of each entity reference of the first entity type with the attribute value of each entity reference of the second entity type. The technique may also include determining one or more resultant entity references from the entity references of the first entity type based on the comparing.

Abstract: The present invention disclosed an application of an antisense oligonucleotide targeting a PBX1 promoter region G-quadruplex in a preparation of a medicine for treating melanoma. The medicine for treating melanoma has one or more of following uses: inhibiting the proliferation of melanoma cell; inhibiting the migration of melanoma cell; inhibiting the invasion of melanoma cell; inhibiting the growth of melanoma; and inhibiting the lung metastasis of melanoma. The identification of the antisense oligonucleotide targeting the PBX1 promoter region G-quadruplex provided by the present invention provides a new drug target and new treatment methods and ideas for the development of a new generation of inhibiting melanoma medicines.

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: Provided is an isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human CD40. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. An immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same are further provided.

Abstract: Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).

Abstract: The present invention provides a storage and sorting method and apparatus, a control device and a storage medium, and relates to the field of logistics. The storing and sorting apparatus of the present disclosure includes: a conveying device configured to convey articles; and at least one storage device, wherein the storage device is located over the conveying device, and is configured to obtain and store the articles conveyed on the conveying device in a storage phase, and release the stored articles to the conveying device in a sorting phase.

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).

Abstract: A method is disclosed for determining flow measurement values of a Coriolis mass flowmeter in the presence of a two-phase flow of a two-phase medium having a gas phase and the subsequent presence of a single-phase flow of a single-phase medium not having a gas phase. The method includes: detecting a start time of a two-phase measurement interval at an onset of the two-phase flow; detecting an end time of the two-phase measurement interval at an end of the presence of the two-phase flow; determining and at least partially storing two-phase flow measurement values of the two-phase flow; determining at least one state variable of the single-phase medium; determining subsequently corrected two-phase flow measurement values as at least indirect input variables of a correction calculation; and outputting the corrected two-phase flow measurement values as individual values or as part of a cumulative flow measurement value.

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: An information push method includes: acquiring a monitoring image captured by a camera; identifying a target group contained in the monitoring image; performing a group relationship recognition on the target group according to attribute data of the target group to recognize a group relationship type of the target group; and pushing a recommendation information to at least one designated terminal corresponding to the target group based on the group relationship type. An information push device and an information push system are also provided.

Abstract: An information push method includes: acquiring a monitoring image captured by a camera; identifying a target group contained in the monitoring image; performing a group relationship recognition on the target group according to attribute data of the target group to recognize a group relationship type of the target group; and pushing a recommendation information to at least one designated terminal corresponding to the target group based on the group relationship type. An information push device and an information push system are also provided.

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: The invention provides a device and a method for detecting a leak in a piping system. The device comprises a conduit for transporting a fluid; a shut-off valve mounted onto the conduit; a flowmeter installed in the conduit and configured to measure a flow rate of the fluid in the conduit; a pressure decay detector configured to measure a pressure change of the fluid in the conduit downstream of the valve; and a controller employing a control logic. The controller comprises a central processing unit. Each of the shut-off valve, the flowmeter, the pressure decay detector is in communication with the controller. The control logic employed by the device and the method comprise that only after at least two consecutive pressure decay tests detect pressure drops in the conduit downstream of the shut-off valve while the shut-off valve is closed, it is ascertained the presence of a micro leak in the piping system.